NCT05904964View on ClinicalTrials.gov

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

PHASE3RecruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2030

Conditions
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Interventions
DRUG

Disitamab vedotin

Disitamab Vedotin 2mg/kg was injected every 2 weeks,

OTHER

Endocrine therapy

Doctors choose endocrine therapy independently

Trial Locations (3)

510000

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

515000

RECRUITING

The Second Affiliated Hospital， Shantou University Medical College, Shantou

571400

RECRUITING

Hainan Qionghai People's Hospital, Qionghai

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER